Antares Pharma Submits NDA For QuickShot Testosterone - Quick Facts

(RTTNews) - Antares Pharma, Inc. (ATRS) announced it had submitted a New Drug Application to the U.S. FDA for QuickShot Testosterone, a drug-device combination product for the delivery of testosterone enanthate using a subcutaneous auto injector. QuickShot Testosterone is intended to treat adult men with low testosterone associated with a condition known as hypogonadism.

The QuickShot auto injector is designed to allow rapid subcutaneous self-administration of highly viscous drugs such as testosterone and biologics using high spring pressure through a fine gauge needle. The QuickShot auto injector can also provide the patient with the ease and speed of self-administration, comfort and discretion.